1. Introduction {#sec0001}
===============

Brain changes in deep grey matter (DGM) structures have been described with some inconsistences ([@bib0037]) in patients with diagnosis of Bipolar Disorder (BD) ([@bib0028]). While the sources of heterogeneity are multifactorial, one much debated source of bias is the effect of mood-stabilizing medications, primarily lithium (the archetypal mood stabilizer), that is already thought to have a modulatory effect in terms of volumetric increase induced on brain structures, particularly hippocampus and amygdala ([@bib0035]; [@bib0048]; [@bib0014]; [@bib0049]).

In recent years, developments in brain morphometric methodologies have led to different structural measures that can integrate data derived from volumetric analysis. Indeed, investigation of the three-dimensional surfaces of DGM structures have been shown to be more sensitive than gross morphometric techniques, identifying group abnormalities where volumetric analyses did not ([@bib0034]). Since shape analysis enables the uncovering of localized changes on the surface of brain structures it can be a very specific neuroimaging measure, especially in the case of structures with explicit regional differentiation in functions, such as DGM ([@bib0027]). Previous studies investigating DGM shape in BD reported that drug-naive and non-psychotic BD patients, compared to healthy controls (HC), show widespread shape alteration of the caudate ([@bib0029]; [@bib0043]; [@bib0033]; [@bib0055]) and putamen ([@bib0033]; [@bib0055]), both as local inward and outward deformations. Significant shape contraction on the dorsal surface of the right accumbens and widespread contractions of the globus pallidus in non-psychotic BD patients have also been reported ([@bib0033]). However, results from these studies did not consider neither the specific effect of lithium treatment nor the effect of its duration relative to illness duration. Indeed, a staging model for bipolar disorder has recently been proposed claiming that a better response to treatment generally occurs when drugs are introduced early in the course of the illness ([@bib0054]). Coherently, this model posits that response to treatment is function of the duration of illness and that the longer untreated duration of illness the longer duration of treatment is necessary in order to be effective. In this perspective, treatment duration should be considered as the balance between the exposure to neuropathological ([@bib0053]) (driven by illness duration) and neuroprotective (driven by lithium treatment) processes.

Finally, the relationship between lithium-driven DGM shape variations and clinical correlates of BD patients, such as the degree of depressive and manic symptoms, has not been investigated.

In the present work, our first aim was to analyse the potential effect of the duration of lithium treatment on the morphometric measures of DGM surfaces. As a secondary goal, we aimed at identifying the relationship between the severity of patients' depressive and/or manic symptomatology and the degree of any localized DGM abnormalities. To these aims we analysed the shape of seven bilateral DGM structures (i.e. Accumbens, Amygdala, Caudate, Hippocampus, Pallidus, Putamen, and Thalamus) in HC and BD samples, both considering BD as a whole group and stratifying it in subsamples, according to lithium treatment duration.

We hypothesize that shape of DGM structures of BD is associated to lithium treatment duration, given the well-established neurotrophic effect of lithium ([@bib0035]). Further, based on previous literature focusing on volume data ([@bib0049]), we predict that differences between BD and HC subjects on DGM surface will be evident only categorizing patients as a function of duration of lithium treatment, such that shape abnormalities would emerge particularly in never treated patients. Finally, we expect that such abnormalities will be associated to the severity of depressive and hypomanic/manic patients' symptomatology, given lithium efficacy in mood stabilization ([@bib0021]).

2. Methods {#sec0002}
==========

This cross-sectional case-control study was approved by the local ethic committee of the Santa Lucia Foundation. All participants provided written informed consent to be included in the study.

Given the lack of prior studies about the relationship between DGM shape morphometry and lithium treatment in bipolar disorder, an a priori power calculation in G\*power was used to determine the minimum sample size. Specifically, we used data from our previous study on hippocampal volumetry in bipolar disorder ([@bib0049]), which showed an effect sizes of 0.85--0.99 for the lithium-dependent modulatory effects, to inform the power calculation. To be conservative we used the lower estimate, which determined that a total sample size of at least 24 subjects would have greater than 95% power to detect a difference between groups, with an alpha value of \<0.05 (two tailed).

Subjects were recruited between May 2013 and March 2017.

2.1. Participants {#sec0003}
-----------------

Eighty patients with a diagnosis of BD (49 BD type I -- 31 BD type II) according to the Diagnostic and Statistical Manual of Mental Disorders IV-Edition, Text Revised (DSM-IVTR) ([@bib0004]) were initially assessed at the Santa Lucia Foundation in Rome. The clinical psychiatrist who had been treating the patients and knew their clinical history, and who was blind to the aims of the study, made the preliminary diagnosis using the DSM- IV-TR criteria. Then, a research psychiatrist using the Structured Clinical Interview for DSM-IV-TR-Patient Edition (SCID-I/P) ([@bib0017]) confirmed the clinical diagnoses. If the diagnoses made at the two different steps were not consistent, more data were gathered and the diagnostic process continued until a final diagnostic consensus was reached. If an agreement could not be reached the patient was not included in the sample. From the original BD group (*n* = 80), two refused to undergo the MRI exam and four were excluded given the low quality of T1-weighted images (see exclusion criteria). The remaining sample of 74 patients included 45 with BD-I and 29 with BD-II.

We also recruited 74 healthy controls (HC) in the same geographical area, paired-matched with the patients for age, gender and educational level. All HC were screened for a current or lifetime history of DSM-IV-TR Axis I and II disorders using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition (SCID-I-NP) ([@bib0016]) and the Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II) ([@bib0015]); they were also assessed to confirm that no first-degree relative had a history of bipolar, mood- or schizophrenia-related disorders.

Apart from these groups-specific inclusion processes, inclusion criteria for all participants were: (i) age between 18 and 75 years, (ii) at least five years of education, and (iii) suitability for magnetic resonance imaging (MRI) scanning. Exclusion criteria were: (i) history of alcohol or drug abuse during the two years before the assessment, (ii) lifetime drug dependence, (iii) traumatic head injury with loss of consciousness, (iv) past or present major medical illness or neurological disorders, (v) any (for HC) or additional (for BD) psychiatric disorder or mental retardation, (vi) dementia or cognitive deterioration according to DSM-IV-TR criteria, and Mini-Mental State Examination (MMSE) ([@bib0019]) score \<25, consistent with normative data in the italian population ([@bib0038]), (vii) low quality of T1-weighted images (i.e. presents of severe motion or scanner-generated artefacts), (viii) any potential brain abnormality or microvascular lesion as apparent on conventional fluid attenuated inversion recovery (FLAIR) scans, potentially explaining critical phenomenology; in particular, the presence, severity, and location of vascular lesions were computed according to the semi-automated method developed by our group ([@bib0030]).

2.3. Clinical assessment {#sec0004}
------------------------

Clinical characteristics were collected during a semi-structured clinical interview and all patients were under stable pharmacologic treatment for at least six months. Age at onset was defined as 'age at onset of first affective symptoms', which were investigated in an interview with patients and first-degree relatives. We also collected specific information about lithium treatment duration (LiTD), reported in months. We categorized patients with LiTD longer than 50% of illness duration (hereafter called LiTD+, *N* = 13), those with LiTD shorter than 50% of illness duration (LiTD-, *N* = 31), and those not taking lithium at all (NoLi, *N* = 30), in order to weight up LiTD as a function of patients' illness duration. This was done in order to obtain better homogeneity (in terms of lifetime drug exposure) of samples to compare with HC group, according to the staging model of BD ([@bib0054]). At the time of MRI scanning, patients in both LiTD+ and LiTD- groups all were still taking lithium.

The severity of affective depressive and hypomanic/manic symptoms was assessed using the 17-item Hamilton Depression Rating Scale (HAM-D) ([@bib0025]), the Beck Hopelessness Scale (BHS) ([@bib0006]) and the Young Mania Rating Scale (YMRS) ([@bib0056]). The amount of depressive symptoms were scored, rating also the psychological (HAM-D~psy~) and somatic components (HAM-D~som~) of depression, apart from the total score (HAM-D tot).

2.4. Image acquisition e processing {#sec0005}
-----------------------------------

All 148 participants underwent the same imaging protocol, which included 3D T1-weighted, T2-weighted and FLAIR sequences using a 3T Achieva MR scanner (Philips Medical Systems, Best, The Netherlands) with a 32-channel receiving-only head coil. Whole-brain T1-weighted images were obtained using a fast-field echo sequence (echo time/repetition: time = 5.3/11 ms, flip angleec = 9°, voxel sizeec = 1 × 1 × 1 mm^3^). T2-weighted and FLAIR sequences were acquired to screen for brain pathology.

Segmentations of seven bilateral subcortical grey matter nuclei (Accumbens, Amygdala, Caudate, Hippocampus, Pallidus, Putamen, and Thalamus) were generated using the FIRST algorithms included in the FMRIB Software Library (FSL, version 5.0.0). Specifically, FIRST is a fully automated model-based segmentation/registration software, providing analysing tools both for volume estimations and localized differences in shape (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FIRST>). The segmentation process is based on the shape and appearance models, constructed from 336 manually segmented images using Gaussian assumptions combined with a Bayesian probabilistic approach ([@bib0044]). FIRST algorithms ascertain the most probable shape by means of linear combinations of shape variations employing the learned manually segmented models. Moreover, the segmentation process includes boundary correction and registration to a MNI152 template using 12 degrees of freedom as well as a subcortical mask to detect and eliminate voxels outside the subcortical structure. Shape was then expressed as a mean with modes of variation (principal components).

After the automated segmentation performed by the software, the outputs were manually checked and confirmed for the proper nuclei extraction of all the subcortical structures. FSLView toolbox was used for neuroimaging results visualizations (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslView>).

In case of significant results located in the nucleus accumbens, we further refined their localization in terms of specific accumbens subregions (i.e. core and shell), by using the Allan Human Brain Atlas ([@bib0026]) (available from: <http://atlas.brain-map.org>) and referring to previous evidence on accumbens anatomy ([@bib0005]) (see Results section).

2.5. Statistical analyses {#sec0006}
-------------------------

Comparisons between HC and BD on sociodemographic variables (i.e. age, gender, and educational level) and between BD subgroups on sociodemographic and clinical (i.e. duration of illness, number of episodes, time of lithium exposure, severity of (hypo)manic/depressive symptoms and pharmacological treatment) characteristics were performed using *t*-test, ANOVA or chi-square tests on StatView statistical software, considering *p* \< 0.05 as statistical threshold for significance.

All neuroimaging statistics were performed by vertex-wise shape analysis along the surface of the segmented DGM structures, using FSL Randomise tool with a nonparametric permutation testing ([@bib0042]). We used *n* = 5000 permutations and a Threshold-Free Cluster Enhancement (TFCE, --T2) to correct for multiple comparisons (*p* \< 0.05, after correction for multiple comparisons) ([@bib0050]).

We preliminary checked for the presence of differences in demographical, clinical ([Table 1](#tbl0001){ref-type="table"}) and DGM morphological features between BD-I and BD-II performing t-tests between patients' subgroups. Since no difference was found between BD subtypes, subsequent analyses were performed considering BD patient groups as a whole.Table 1Sociodemographic and clinical characteristics of 45 BD-I and 29 BD-II patients.Table 1CharacteristicsBD-IBD-IItdf*p*Age (years), mean (SD)43.51 (12.9)44.65 (11.7)−0.39720.70Educational level (years), mean (SD)13.76 (3.3)14.83 (2.9)−1.37720.174Duration of illness (years), mean (SD)14.7 (11.6)15.38 (9.2)−0.27720.788Duration of lithium treatment (months)63.84 (54.5)38.38 (30.2)1.577420.122[^1]

The effect of lithium treatment duration on BD DGM was investigated using FSL Randomise as follows: first, linear regressions were performed between each DGM shape measure of BD (continuous dependent variable) and LiTD (continuous independent variable), including the duration of illness as covariate of no interest. The inclusion of the covariate was justified by the significant association with the independent variable (*r*^2^ = 0.125, *p* = 0.0186). Second, in case of significant linear regressions results, we compared BD and HC either considering patient group as a whole, either dividing patients in three groups based on LiTD. In the first case, DGM of BD and HC were compared using *t*-test while in the second case, ANOVA analyses were conducted, using shape as dependant variable and group (i.e. LiTD+, LiTD-, NoLi, HC groups) as four-level independent variable. We performed the last two analyses in order to assess whether the impact of the duration of lithium treatment is crucial to bring out differences between patients and controls and to investigate in which time point of medication they could be evident. Moreover, categorizing patient according to treatment duration, we investigated if lithium-associated DGM morphological characteristics found in BD were similar to these observed in physiological states. T-tests were performed for post-hoc comparisons. The relationship between values of inward/outward deformations in BD patients (independent variable) and clinical symptoms severity (i.e. HAM-D~tot~, HAM-D~psy~, HAM-D~som~, BHS~tot~) (dependent variable) was subsequently assessed performing linear regressions. We focused subsequent ANOVA post-hoc (pairwise comparisons) and linear regressions (surface deformations vs. symptom severity) analyses in those areas where significant surface outward or inward deformations emerged from results of the main ANOVA analysis.

3. Results {#sec0007}
==========

3.1. Sociodemographic and clinical characteristics {#sec0008}
--------------------------------------------------

Sociodemographic characteristics of BD (as a whole) and HC groups are shown in [Table 2](#tbl0002){ref-type="table"}. As expected, in view of the matching procedure, the groups did not differ in terms of age, gender or educational level ([Table 2](#tbl0002){ref-type="table"}). No differences were also found when HC were compared to BD subgroups (NoLi, LiTD- and LiTD+) ([Table 3](#tbl0003){ref-type="table"}). Furthermore, the NoLi, LiTD- and LiTD+ subgroups did not differ in terms of duration of illness, number of past episodes, HAM-D scores, YMRS scores, or -- with the exception of lithium exposure -- current and past pharmacotherapies ([Table 3](#tbl0003){ref-type="table"}).Table 2Sociodemographic and clinical characteristics of 74 BD patient and, 74 healthy subjects.Table 2CharacteristicsBDHC*t* or χ^2^dfpAge (years), mean (SD)43.96 (12.4)43.96 (17.2)0.00146--Males, *n* (%)42 (56.8)42 (56.8)0.001--Educational level (years), mean (SD)14.2 (3.3)14.8 (2.9)−1.221460.22Duration of illness (years), mean (SD)14.9 (10.7)--------Number of past manic/hypomanic episodes, mean (SD)5 (6.2)--------Number of past depressive episodes, mean (SD)6.2 (6.4)--------HAM-D score, mean (SD)7.7 (5.6)--------YMRS score, mean (SD)5 (6)--------Current medication, *n* (%)74 (100)--------Antidepressant, *n* (%)29 (39.2)--------Antipsychotics, *n* (%)47 (63.5)--------Lithium, *n* (%)44 (59.5)--------Benzodiazepines, *n* (%)29 (39.2)--------Other mood-stabiliser, *n* (%)48 (65.8)--------[^2]Table 3Sociodemographic and clinical characteristics of 74 healthy subjects and 74 BD patients stratified according to lithium treatment duration: 31 BD_LiTD-; 13 BD_LiTD+; 30 BD_NoLi.Table 3CharacteristicsBD \_LiTD-BD \_LiTD+BD \_NoLiHCt, F or χ2dfpAge (years), mean (SD)44.7 (13)45 (11)42.7 (12)43.9 (17)0.1130.952Males *n* (%)22 (71)6 (46.2)14 (46.7)42 (57)4.3930.111Educational level (years), mean (SD)14.7 (3.5)14.3 (3)13.6 (3.1)14.8 (2.8)1.230.312Duration of illness (years), mean (SD)17.2 (10.5)11.5 (9.1)14.3 (11)--0.21710.319Duration of lithium treatment (months), mean (SD)41.4 (34)91.8 (63)----−3.4420.0013\*Number of past manic/hypomanic episodes, mean (SD)4.1 (3)4.2 (3.1)6.31 (9)--1.1220.336Number of past depressive episodes, mean (SD)5.4 (4)5.9 (4)7 (8.9)--0.4620.633HAM-D score, mean (SD)7.2 (6.6)6.8 (5.6)8.5 (4.4)--0.5920.559YMRS score, mean (SD)3.2 (4.3)6.7 (5.5)6.2 (7.3)--2.6920.075Antidepressant, *n* (%)10 (32.3)3 (23.1)16 (53.3)--4.5620.102Antipsychotics, *n* (%)20 (64.5)8 (61.5)19 (63,3)--0.0420.982Benzodiazepines, *n* (%)13 (41.9)4 (30.8)12 (40)--0.4920.781Other mood-stabiliser, *n* (%)22 (45.8)9 (18.8)17 (35.4)1.93520.381[^3]

3.2. Shape analysis {#sec0009}
-------------------

Either comparisons between BD-I and BD-II patients or between HC and BD (considered as a single diagnostic group) did not show significant shape differences in any of the analysed DGM structures.

The linear relationship between LiTD and DGM shape in BD indicated both positive and negative significant associations between the duration of lithium treatment and the morphometric characteristics of clusters located on the bilateral nucleus accumbens (R-Accu and L-Accu). In order to qualify the localization of significant changes in terms of specific accumbens subregions (i.e. core or shell), we both referred results to the standard Human Brain Atlas ([@bib0026]) (available from: <http://human.brain-map.org>) and to previous evidence for human nucleus accumbens anatomy ([@bib0005]) described by the MNI coordinates, which anatomically defined the core and the shell of the nucleus accumbens. According to y-axis coordinate and to boundaries obtained from Human Brain Atlas ([@bib0026]), our results could be selectively located on the surfaces of the accumbens nuclei core or shell. Specifically, we found positive bilateral correlations in clusters on the accumbens core sub-field (statistical peaks: corrected p~R-AccuCore~ = 0.016; corrected p~L-Accu-Core~ = 0.031) indicating that the longer lithium treatment duration, the more outward is the bending of the cluster on the core (i.e. core extroflection). Moreover, we found a negative correlation between shape and lithium treatment duration in a cluster on the boundary of the R-Accu shell sub-field (statistical peak: corrected p~R-Accu-Shell~ = 0.002), indicating that lithium treatment duration is associated with inward bending in this sub-region (i.e. shell introflection) ([Fig. 1](#fig0001){ref-type="fig"}).Fig. 1Relationship between patients' lithium treatment duration and nucleus accumbens shape morphometry. Linear regression results using lithium treatment duration (months) and accumbens nuclei shape deformations (distance from mean template, mm^3^) as variables of interest are shown. (a) right accumbens shell; (b) right accumbens core and (c) left accumbens core; (d) Statistical maps for significant (TFCE-corrected) right/left accumbens core inward and right accumbens shell outward deformations (in red) superimposed onto representative nucleus accumbens masks (light blue). Borders of shell and core nuclei are drawn using solid black lines and taken from the Human Brain Atlas. Image credit: Allen Institute. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 1

When splitting the BD group in terms of LiTD (LiTD+, LiTD-, NoLi and HC), ANOVA performed on R-Accu and L-Accu shape showed significant bilateral results (statistical peaks: corrected p~L-Accu-ANOVA~ = 0.025; corrected p~R-Accu-ANOVA~ = 0.025) ([Fig. 2](#fig0002){ref-type="fig"}). Post-hoc t-tests revealed R-Accu shell outward deformation in the NoLi group compared to LiTD+ (statistical peak: corrected p~R-Accu-Shell~ = 0.016) and HC (statistical peak: corrected p~R-Accu-Shell~ = 0.002). Moreover, the LiTD- group showed L-Accu core inward deformation compared to HC (statistical peak: corrected p~L-Accu-Core~ = 0.027). Details on results and clusters coordinates are shown in [Table 4](#tbl0004){ref-type="table"}.Fig. 2Comparison between healthy subjects and patients with bipolar disorder stratified according to lithium treatment duration. (a) 3D visualization of ANOVA results: right accumbens shell outward and left accumbens core inward deformations (in red) superimposed onto a representative nucleus accumbens mask (in blue); (b) Mean total deformation (distance from mean template, mm^3^) of right accumbens shell (light grey) and left accumbens core (orange) in patients with lithium treatment duration longer/shorter then 50% of illness duration (respectively, BD_LiTD+, BD_LiTD-), patients never treated with lithium (BD_NoLi) and healthy subjects (HC) groups. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 2Table 4Neuroimaging Results. Topography and statistical details of significant relationships between BD LiTD and boundary deformation on the left/right accumbens nuclei shape morphometric features. Effects have been assessed through linear regression analyses and ANOVA comparisons between BD groups stratified according to LiTD (i.e. BD_LiTD-, BD_LiTD+, BD_NoLi) and HC and related post-hoc analyses. Clinical correlates (depressive/hopefulness BD symptoms scores) of [L]{.smallcaps}-Accu core inward deformation are also reported.Table 4Anatomical regionResultsCluster Extent (mm^3^)*R^2^/F/t*Statistical peak *p* (TFCE-corrected)MNI Coordinates of the statistical peakxyz*Regression Analyses*Left Nucleus Accumbens corePositive Correlation680.10.031[\*](#tb4fn1){ref-type="table-fn"}−1519−6Right Nucleus Accumbens corePositive Correlation560.120.016[\*](#tb4fn1){ref-type="table-fn"}1014−4Right Nucleus Accumbens shellNegative Correlation1360.170.002[\*](#tb4fn1){ref-type="table-fn"}813−10*ANOVA*Left Nucleus Accumbens core47F~(3;144)~ = 4.60.01[\*](#tb4fn1){ref-type="table-fn"}−1116−4Right Nucleus Accumbens shell55F~(3;144)~ = 3.50.025[\*](#tb4fn1){ref-type="table-fn"}813−9*Post-Hoc*Left Nucleus Accumbens coreBP_LiTD- \< HC172.720.027[\*](#tb4fn1){ref-type="table-fn"}−1016−9Left Nucleus Accumbens coreBP_NoLi \< HC473.50.002[\*](#tb4fn1){ref-type="table-fn"}−1016−9Left Nucleus Accumbens coreBP_NoLi \< BP_LiTD+472.320.016[\*](#tb4fn1){ref-type="table-fn"}−109−6Right Nucleus Accumbens shellBP_NoLi \> BP_LiTD+553.110.005[\*](#tb4fn1){ref-type="table-fn"}814−10Right Nucleus Accumbens shellBP_NoLi \> HC552.580.005[\*](#tb4fn1){ref-type="table-fn"}1018−9*Clinical Correlates of Left Nucleus Accumbens core*HAM-DsomPositive Correlation430.10.005[\*](#tb4fn1){ref-type="table-fn"}−1210−6HAM-DtotPositive Correlation410.070.02[\*](#tb4fn1){ref-type="table-fn"}−129−6BHStotPositive Correlation180.050.03[\*](#tb4fn1){ref-type="table-fn"}−916−3[^4][^5]

The shape of BD L-Accu-Core was positively correlated with HAM-D~tot~ (statistical peaks: corrected p~L-Accu-core~ = 0.02), HAM-D~som~ (statistical peaks: corrected p~L-Accu-core~ = 0.005) and BHS~tot~ (statistical peaks: corrected p~L-Accu-core~ = 0.03) scores ([Table 4](#tbl0004){ref-type="table"}, [Fig. 3](#fig0003){ref-type="fig"}), indicating the more inward deformation the higher depression symptom severity. No significant associations were found for YMRS~tot~ scores.Fig. 3Clinical correlates of left accumbens inward deformation. Relationship between deformations resulted from ROI ANOVA and patients depressive/hopelessness symptom scores, assessed through (a) Somatic subscale of Hamilton Depression Rating Scale (HAMDsom); (b) Total score of Hamilton Depression Rating Scale (HAM-Dtot); (c) Total score of Beck Hopelessness Scale (BHStot).Fig. 3

4. Discussion {#sec0010}
=============

Despite a substantial amount of research over the past decades has been focused on neurotrophic and neuroprotective effects of lithium, this is the first report describing an association between lithium treatment duration and Accu shape in patients diagnosed with BD. Here we show that patients without or even with short-term personal history of lithium treatment have outward R-Accu shell and inward L-Accu core surface changes, when compared to both healthy individuals and patients under long-term lithium treatment. Moreover, in patients we showed that the increased duration of lithium treatment was associated with both an extroflection effect on the core of bilateral Accu and a concomitant introflection effect on the shell of R-Accu. Both these effects showed that the longer duration of treatment the strongest shape modulations, bringing patient whit longer treatment to have an Accu morphology similar to that of healthy controls. We also found that inward deformation of [L]{.smallcaps}-Accu core shape is significantly correlated with increased depression severity.

A small number of previous studies ([@bib0029]; [@bib0043]; [@bib0033]; [@bib0055]; [@bib0051]) investigated the shape of brain regions in patients with BD and half of them were restricted to the caudate ([@bib0029]; [@bib0043]) and putamen nuclei alone ([@bib0043]) or did not consider DGM structures at all ([@bib0051]). Among the remaining studies, findings led to inconsistent results ([@bib0033]; [@bib0055]) especially for the nucleus accumbens. Indeed, [@bib0033] found a dorsal contraction of the right nucleus accumbens that partially overlaps with our results, while [@bib0055] did not. Moreover, no studies to date considered lithium treatment as a potential mediator of brain shape despite a modulatory effect of lithium treatment was clearly described on other morphometric brain measures, such as volume ([@bib0028]; [@bib0049]; [@bib0046]) and cortical thickness ([@bib0022]). Indeed, lithium treatment was associated with volume preservation of deep grey matter assemblies (e.g. hippocampus, amygdala, thalamus and basal ganglia) and cortical thickening in frontal, parietal and occipital regions as well as in the precuneus and precentral areas ([@bib0002]). This was also confirmed by post-mortem studies demonstrating lower numbers of neurons among individuals with BD who are lithium-treatment naïve ([@bib0007]; [@bib0009]).

The Accu has dopamine as a principal neurotransmitter and animal studies described that lithium modulates neuronal activity and dopamine neurotransmission in models of BD. In particular, Clock-Δ19 mice have higher dopamine levels in the Accu area ([@bib0011]) and display behaviours that are very similar to those found in human BD (i.e. increased exploratory drive in novel environments, significant reduction in sleep, decreased anxiety related behaviours, and increase in cocaine preference). Chronic administration of lithium decreases Clock-Δ19 mice dopamine tissue levels in the Accu and reverses many of the phenotypes of Clock-Δ19 mice. Consistently with our morphological results, it has been demonstrated that dopamine neurotransmission modulates different responses of core and shell Accu neurons and depletion of dopamine release from the ascending pathway differently affect the morphology of medium spiny neurons of the two Accu districts ([@bib0039]). Specifically, in animal models dopamine depletion is associated with a significant reduction of the dendritic length of neurons in the core but not in the shell, which show a more tortuous morphology instead. It could be the case that an initial pathogenetic condition in BD lithium naïve patients is characterized by increased level of tonic dopamine, inducing oxidative neuronal loss with a concomitant reduction of dopaminergic connections. Then, dopamine deflection consequent to oxidative neuronal loss can lead to shorter dendrites in the core resulting in an inward surface deformation. Since the same input (dopamine deflection) causes an opposite effect on the neuronal dendrites of the shell, here the pathological oxidative process could lead to a more tortuous internal organization, ending in an outward surface deformation.

A number of mechanisms have been recognized as associated to the neuroprotective/neurotrophic effects of lithium that could be useful in interpreting our results. The inhibition of a protein kinase having a pro-apoptotic action (i.e. glycogen synthase kinase-3, GSK-3), the induction of intracellular molecular survival pathway, and the stimulation of GABAergic neurotransmission, are those having the most direct evidence ([@bib0032]). By stimulating inhibitory GABAergic neurotransmission while reducing the excitatory dopaminergic one ([@bib0032]; [@bib0010]), lithium reduces the neuronal loss due to oxidative stress and promotes neuronal plasticity ([@bib0023]). Some of these mechanisms, or probably all these coupled together, could be responsible for grey matter shape remodelling, even if the precise underling biochemical mechanism of this drugs remain poorly defined. Based on the hypothesis suggested by [@bib0052], the shapes of specific brain structures may be determined by the physical properties of neural tissue combined to the patterns of neural connectivity and biochemical mechanism mediating the neural signalling cascades. Being a dynamic process, it drives normal conditions, neurodegenerative and neurorestorative processes. In this context, lithium treatment could act as a trigger that elicits an extensive reprogramming of BD pathological baseline condition, finally resulting in shape remodelling.

The Accu is connected to the limbic and extrapyramidal motor systems. Recent evidence ([@bib0031]) suggests that Accu D1 and D2 dopamine receptors in Accu core and shell receive similar inputs from diverse sources. Inputs to the core are broadly scattered whereas inputs to the shell are relatively concentrated around DGM. Specifically, the anterior cortex preferentially innervates the core for both D1 and D2, whereas the lateral hypothalamic area preferentially targets D1 in the shell. Acting as a limbic-motor interface, the Accu regulates motivation and emotional processes and is involved in a number of the most disabling neuropsychiatric disorders ([@bib0036]; [@bib0013]; [@bib0041]; [@bib0020]). Moreover, it is part of a circuit including the hippocampus, the amygdala, the prefrontal cortex and other regions mediating emotional memory and anxiety ([@bib0020]). As such, the Accu has a central role in the cerebral reward system. It integrates excitatory inputs from these regions triggering emotionally motivated behaviours through cortico-striatal-thalamic loops within the basal ganglia, eventually driving the dorsolateral striatum to facilitate action related behaviours ([@bib0018]). These local and global Accu circuit interactions mediate motivated and emotional behaviour, making them an attractive focus to study affective disorders such as BD and depression. Evidence for reward and dopamine neural systems alterations in mood disorders, like mania, major depression and BD, have been widely reported both in humans and animal models ([@bib0020]; [@bib0001], [@bib0003]; [@bib0047]; [@bib0040]; [@bib0008]). Furthermore, it has been proposed a "dopamine dysregulation syndrome" model for the BD pathophysiology ([@bib0008]), where a cyclical dysregulation in quantitative dopaminergic transmission is the main construct. Despite our work does not directly asses dopamine transmission, it supports this model showing a complex pattern of lithium-dependant surface modulatory effects on such central node for dopamine and rewarding systems.

The second important result of the present study is the association between [L]{.smallcaps}-Accu core area inward deformation and both hopelessness and depressive symptom severity. Recently, a more accurate way for characterizing Accu functions has been proposed overcoming the pedantic view that it merely acts as a reward centre relay ([@bib0018]). Specifically, the Accu is involved in the modulation of cerebral processing of motivationally relevant goals by promoting likelihood, efficiency, and vigour of behaviours intended to obtain those goals, driving exploration of novel stimuli and procurement of things worth having (rewards) or the avoidance of aversive consequences. Moreover, the core and shell areas modulate different functions in this motivational process: the core has a more prominent role in instigating approach behaviour toward motivationally relevant stimuli ("go to it" function) while the shell drives behaviour to stay on tasks until the rich of a goal ("stay to it" function), suppressing irrelevant or non-rewarded actions.

Our results of increased [L]{.smallcaps}-Accu core inward deformation associated with higher depressive symptom severity support the hypothesis of a decreasing "go to it" brain signalling as pathophysiological correlate of depressive phenomenology in BD. A recent theory was proposed to integrate the hopelessness theory of depression ([@bib0003]) and [@bib0012] approach/withdrawal motivational theory of depression, based on the evidence that individual with high vulnerability to cognitive distress resulted in higher hopelessness and depression scores and fewer motivated goal-directed behaviour ([@bib0024]). Amotivational/anhedonic features are crucial components of depression and, interestingly, the left lateralized finding of Accu core deformation in BD may be explained by the crucial role of the dominant hemisphere in motivational behaviours ([@bib0045]). Studies conducted over several decades support the use of long-term lithium treatment to prevent depression relapse in patients with bipolar disorder ([@bib0021]). In this context, our findings may reflect one of the neurobiological mechanisms underpinning the therapeutic effect of lithium, as part of its efficacy on preventing depression that may unfold through a long-term remodelling of cortical-subcortical connections related to the motivational/hedonic dimension.

5. Limitations {#sec0011}
==============

Several issues have to be considered before concluding. First, the sample size of LiTD+ group is relatively small. However, it is adequate to detect shape differences because of the moderate to large effect size we observed. Second, our results come from a cross-sectional study design and should be replicated also with a longitudinal approach for definitively demonstrating a causal effect between lithium exposure and Accu neuroprotection. Third, our patients were treated also with different psychotropic drugs that might potentially affect Accu shape. However, it could be noted that BD subgroups showed no differences in terms of non-lithium pharmacological drugs, making unlikely the probability that they may have influenced our results.

Finally, the criterium adopted here for categorising BD patients according to the 50% ratio between illness and treatment duration could be considered as arbitrary. However, as posited by the staging model of BD ([@bib0054]), the impact of pharmacological treatment should be considered relatively to illness duration rather than in its absolute value, assuming the construct that the earlier intervention the better efficacy. From the other side, it should be thought that the longer time of brain exposure to pathological conditions the stronger intervention is needed to counteract the illness. Therefore, we chose the 50% threshold since it distinguishes patients having more exposure to potential neuroprotective effects (driven by lithium treatment) than to neuropathological processes (driven by the illness) from patients showing the opposite pattern. In practical terms, the 50% ratio represent the "zero" point as reference to the balance between neuropathological and neuroprotective effects.

6. Conclusions {#sec0012}
==============

Lithium treatment affects Accu surface morphology in BD, with different impacts on core and shell. Differences between BD and HC on Accu shape morphometry are significant in patients never treated with lithium but they progressively decrease and disappear in patients under long-term treatment. Lithium treatment dependent surface deformations of [L]{.smallcaps}-Accu core showed significant correlations with the severity of depressive phenomenology, being the less inward deformation associated to the lower depression symptoms, especially in terms of somatic and hopefulness components. Taken together our results suggest that the duration of lithium treatment is associated with the modulation of Accu shape as part of the mechanism of action possibly linked with its mood stabilizing effects.
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[^1]: df, degrees of freedom; SD, standard deviation.

[^2]: df, degrees of freedom; SD, standard deviation; HAM-D, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale.

[^3]: *df, degrees of freedom; SD, standard deviation; HAM-D, Hamilton Depression Rating Scale; YMRS, Young Mania Rating Scale. \*Statistically significant differences at p* *\<* *0.05.*

[^4]: TFCE, Threshold-Free Cluster Enhancement; Coordinates are in Montreal Neurological Institute (MNI) Space. BD_LiTD-, bipolar disorder patients with lithium duration treatment shorter then 50% of illness duration; BD_LiTD+, bipolar disorder patients with lithium duration treatment longer then 50% of illness duration; BD_NoLi, bipolar disorder patients never treated with lithium; HC, healthy control subjects. HAM-Dsom, somatic subscale from Hamilton Depression Rating Scale; HAM-Dtot, total score from Hamilton Depression Rating Scale; BHStot, total score from Beck Hopefulness Scale.

[^5]: *Statistically significant differences at p* *\<* *0.05.*
